home.aspx
 
EVENTS

Vital Signs EMS Conference
VITAL SIGNS EMS CONFERENCE
October 29-01, 2020
Vital Signs EMS Conference will be showcasing many of the extraordinary aspects of EMS and healthcare found only in Saratoga Springs. This event provided high quality and cutting edge EMS education by providing access to national and world-renowned educators through a forum that is accessible and af...

Internal Medicine for Primary Care
INTERNAL MEDICINE FOR PRIMARY CARE
October 30-01, 2020
The Internal Medicine for Primary Care conference will cover areas like Internal Medicine for Primary Care Physicians, Issues in Women's Health Cardio, Pulmonary for Primary Care Physicians, Neurology for the Non-Neurologist.

Astellas Pharma

SHARESHARESHARE
Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology.
SHARESHARESHARE

RELATED NEWS


Astellas Pharma US, ("Astellas") and the Astellas Global Health Foundation are each expanding support for global and local communities fighting COVID-19 by providing up to $2 million of new financial assistance, in aggregate, to meet the urgent demand for resources to help patients, healthcare workers and first responders. At a national level in the United States, Astellas is preparing to help humanitarian organizations working to support the community due to the COVID-19 outbreak. Thi...

READ MORE

Astellas Pharma has announced the initiation and dosing of the first patient in its SKYLIGHT1 Phase III pivotal trial for fezolinetant. The investigational oral, non-hormonal compound is being studied for the treatment of moderate-to-severe menopause related vasomotor symptoms VMS, such as hot flashes and night sweats. The first trials of the programme will evaluate the efficacy and safety of 30 and 45 mg once-daily (QD) doses of fezolinetant in reducing VMS frequency and severity. “There ...

READ MORE

Seattle Genetics and Tokyo-based Astellas Pharma announced positive topline data from the first cohort of its Phase II EV-201 trial. The trial is evaluating enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who had previously received both platinum-based chemotherapy and a checkpoint inhibitor. Enfortumab vedotin is an antibody-drug conjugate (ADC) targeting Nectin-4. Nectin-4 is highly expressed in urothelial cancers, as well as other solid tumors. The drug re...

READ MORE

Astellas’ experimental acute myeloid leukaemia drug gilteritinib has been awarded orphan drug designation by the European Commission. The decision indicates that the regulator believes the drug may be of significant benefit to patients with the rare condition, of which there are around 13,000 new cases diagnosed in Western Europe every year. Gilteritinib is being developed for adult patients with FLT3 mutation-positive relapsed or refractory AML, which is associated with especially poor ou...

READ MORE

Astellas Pharma Inc. (TSE:4503) and Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today top-line results indicating that the Phase III clinical trial of linaclotide conducted in Japan in adults with chronic constipation (CC) met its primary endpoint....

READ MORE

Astellas Pharma Europe Ltd., a subsidiary of Astellas Pharma Inc. (TSE:4503), is pleased to announce that Mr Yukio Matsui has been appointed as President of EMEA Operations, with responsibility for the company's commercial operations inEurope, the Middle East and Africa. Yukio will assume his new position on 1st April 2016. Since April 2015, Yukio has served as Senior Vice President, Head of Marketing Strategy for Astellas’ global strategic products....

READ MORE

Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and LEO Pharma A/S (President and CEO: Gitte P. Aabo, “LEO Pharma”) today announced that the two companies completed the relevant closing conditions on March 31, 2016 to allow the transfer of the Astellas’ global dermatology business to LEO Pharma from 0 a.m. on April 1....

READ MORE

The World Anti-Doping Agency (President: Sir Craig Reedie, “WADA”) and Astellas Pharma Inc. (TSE: 4503: President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced a global agreement to partner on the prevention of misuse and abuse of medicines f or doping in sports. Doping in sports relies primarily on the misuse and abuse of commercially available medicines, as well as compounds in development that are not as well-known or easily detected....

READ MORE

Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s shareholders have entered into an agreement for Astellas to acquire Ganymed. The transaction would enable Astellasto continue to build upon its leading oncology franchise as a platform for sus...

READ MORE

A $110 million bet on a prostate cancer medicine gave Astellas Pharma Inc. a blockbuster that helped turn it into one of Asia’s most valuable drugmakers. Now, with patent expirations looming in 2019, Chief Executive Officer Yoshihiko Hatanaka is setting off on a hunt for his next best seller....
BLOOMBERG.COM
READ MORE

EVENTS

Internal Medicine for Primary Care
INTERNAL MEDICINE FOR PRIMARY CARE
October 30-01, 2020
The Internal Medicine for Primary Care conference will cover areas like Internal Medicine for Primary Care Physicians, Issues in Women's Health Cardio, Pulmonary for Primary Care Physicians, Neurology for the Non-Neurologist.

Symposium on Advanced Wound Care Fall
SYMPOSIUM ON ADVANCED WOUND CARE FALL
October 30-01, 2020
The Symposium on Advanced Wound Care Fall meeting (SAWC Fall) serves as a forum to connect the entire wound care team — physicians, nurses, physical therapists, researchers, scientists, podiatrists, and dietitians — with the foremost experts in wound care to improve patient outcomes thro...